Core Viewpoint - The announcement by the company regarding the approval of its fluticasone propionate nasal spray marks a significant step in breaking the market monopoly of foreign products in the domestic allergic rhinitis treatment sector [2]. Group 1: Product Development and Market Position - The fluticasone propionate nasal spray is the first domestic generic product to be launched in China and has been included in the national medical insurance and essential drug lists [2]. - The company has established itself as one of the leading firms in the domestic market for allergic rhinitis treatments, with a comprehensive product pipeline [2]. - The respiratory and critical care segment generated approximately HKD 1.71 billion in revenue last year, reflecting a nearly 27% year-on-year growth [2]. Group 2: Future Development Strategy - The company plans to continue its strategy of independent research and global expansion, focusing on developing a comprehensive product cluster for chronic airway diseases and critical care [3].
远大医药：丙酸氟替卡松鼻喷雾剂获批 脓毒症创新产品将于近期公布临床结果